American Association for Cancer Research

Skip to Main Content

Table 1

HLA type of patients enrolled in study

HLA-A, -B, and -DR were determined on aliquots of PBMCs at the time of entry into the study.
Patient	HLA-A	HLA-B	HLA-DR
VC9421	24,26	14,45	ND^a
LR3530	1	8	3,11
KK8169	3,24	35,51	ND*
CZ8474	24	49,62	11,13
TS5437	1,28	37,62	4,10
ER9519	3,29	35,44	1,7
DG4965	1,23	7	1,10
CC7062	1,2	27	1,11

HLA-A, -B, and -DR were determined on aliquots of PBMCs at the time of entry into the study.
Patient	HLA-A	HLA-B	HLA-DR
VC9421	24,26	14,45	ND^a
LR3530	1	8	3,11
KK8169	3,24	35,51	ND*
CZ8474	24	49,62	11,13
TS5437	1,28	37,62	4,10
ER9519	3,29	35,44	1,7
DG4965	1,23	7	1,10
CC7062	1,2	27	1,11

^a

ND, not determined. Inadequate number of lymphocytes available.